Tags

Type your tag names separated by a space and hit enter

Microbial manipulation as primary therapy for Crohn's disease.
World J Gastroenterol. 2013 Mar 14; 19(10):1513-6.WJ

Abstract

While antimicrobials are clinically effective in preventing post-operative recurrence, the role for antibiotics in primary therapy for Crohn's disease (CD) remains unclear. The recent multicenter phase 2 trial by Prantera et al received wide attention because it demonstrated an increase in the week 12 remission rate in patients with moderately active CD treated with rifaximin and renewed interest in microbial manipulation as primary therapy for CD. In this commentary, we discuss aspects of durability, immune cell polarization, and safety of microbial manipulation as primary therapy for CD.

Authors+Show Affiliations

Division of Digestive and Liver Disease, Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23539531

Citation

Longman, Randy S., and Arun Swaminath. "Microbial Manipulation as Primary Therapy for Crohn's Disease." World Journal of Gastroenterology, vol. 19, no. 10, 2013, pp. 1513-6.
Longman RS, Swaminath A. Microbial manipulation as primary therapy for Crohn's disease. World J Gastroenterol. 2013;19(10):1513-6.
Longman, R. S., & Swaminath, A. (2013). Microbial manipulation as primary therapy for Crohn's disease. World Journal of Gastroenterology, 19(10), 1513-6. https://doi.org/10.3748/wjg.v19.i10.1513
Longman RS, Swaminath A. Microbial Manipulation as Primary Therapy for Crohn's Disease. World J Gastroenterol. 2013 Mar 14;19(10):1513-6. PubMed PMID: 23539531.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Microbial manipulation as primary therapy for Crohn's disease. AU - Longman,Randy S, AU - Swaminath,Arun, PY - 2012/06/20/received PY - 2013/02/05/revised PY - 2013/02/07/accepted PY - 2013/3/30/entrez PY - 2013/3/30/pubmed PY - 2013/12/16/medline KW - Inflammatory bowel disease KW - Microbiome KW - Rifaximin SP - 1513 EP - 6 JF - World journal of gastroenterology JO - World J. Gastroenterol. VL - 19 IS - 10 N2 - While antimicrobials are clinically effective in preventing post-operative recurrence, the role for antibiotics in primary therapy for Crohn's disease (CD) remains unclear. The recent multicenter phase 2 trial by Prantera et al received wide attention because it demonstrated an increase in the week 12 remission rate in patients with moderately active CD treated with rifaximin and renewed interest in microbial manipulation as primary therapy for CD. In this commentary, we discuss aspects of durability, immune cell polarization, and safety of microbial manipulation as primary therapy for CD. SN - 2219-2840 UR - https://www.unboundmedicine.com/medline/citation/23539531/Microbial_manipulation_as_primary_therapy_for_Crohn's_disease_ L2 - http://www.wjgnet.com/1007-9327/full/v19/i10/1513.htm DB - PRIME DP - Unbound Medicine ER -